


AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A compound represented by the formula (I):



wherein R⁷ and R²¹ are the same or are different and represent

-O-benzoyl,

OH, or

RC(=Y)-O-, wherein Y represents an oxygen atom, and R represents

piperazinyl, alkyl, -O-phenyl, -N-alkyl or -NH-phenyl,

a C₆ to C₁₄ aryl group which may have a substituent, or

a C₆ to C₁₄ aryloxy group which may have a substituent, or

R^{N1} R^{N2} N R^M, wherein R^M represents

a) a single bond,

b) CO O-,

c) CS O- or

d) CO NR^{N3}, wherein R^{N3} represents a hydrogen atom or a C₁ to C₆ alkyl group

which may have a substituent, provided that, the leftmost bond in b) to e) is

bonded to the nitrogen atom, and

wherein R^{N1} and R^{N2} are the same or are different and represent


- a) a hydrogen atom,
- b) a C_1 to C_{22} alkyl group which may have a substituent,
- c) an unsaturated C_2 to C_{22} alkyl group which may have a substituent,
- d) an aliphatic C_2 to C_{22} acyl group which may have a substituent,
- e) an aromatic C_7 to C_{15} acyl group which may have a substituent,
- f) a C_6 to C_{14} aryl group which may have a substituent,
- g) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- h) a C_7 to C_{22} aralkyl group which may have a substituent,
- i) a C_1 to C_{22} alkylsulfonyl group which may have a substituent,
- j) a C_6 to C_{14} arylsulfonyl group which may have a substituent,
- k) a 3-membered to 14-membered non-aromatic heterocyclic group formed by R^{N1} and R^{N2} together in combination with the nitrogen atom to which R^{N1} and R^{N2} are bonded, wherein the 3-membered to 14-membered non-aromatic heterocyclic group may have a substituent,
- l) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,
- m) a C_3 to C_{14} cycloalkyl group which may have a substituent or
- n) a 3-membered to 14-membered non-aromatic heterocyclic group which may have a substituent; or

a pharmacologically acceptable salt thereof, thereof.

wherein said substituents are each independently selected from the group consisting of:
 C_1 - C_6 alkyl group, phenyl group, halogen, hydroxyl group, C_1 - C_6 alkoxy group, thiol group, C_1 -

~~C₆-alkylthio group, nitro group, nitroso group, cyano group, C₁-C₆ alkoxy carbonyl group, amino group, mono (C₁-C₆ alkyl) amino group, di (C₁-C₆ alkyl) amino group, pyrrolidyl group, piperadyl group, piperidyl group and pyridyl group.~~

2. (Currently Amended) The compound according to claim 1 represented by the formula (I-a):



wherein R^{7a} and R^{21a} are the same or are different and represent

R^aC(=Y^a)-O-, wherein Y^a represents an oxygen atom, and R^a represents

~~a C₆ to C₁₄ aryl group which may have a substituent, or~~

~~a C₆ to C₁₄ aryloxy group which may have a substituent, or~~

~~R^{aN1}R^{aN2}N-CO-O-, wherein R^{aN1} and R^{aN2}, the same or different, represent~~

~~a) a hydrogen atom,~~

~~[[b)]] a C₁ to C₂₂ alkyl group which may have a substituent,~~

~~[[c)]] an unsaturated C₂ to C₂₂ alkyl group which may have a substituent,~~

~~d) a C₆ to C₁₄ aryl group which may have a substituent,~~

~~e) a 5-membered to 14-membered heteroaryl group which may have a substituent,~~

~~f) a C₇ to C₂₂ aralkyl group which may have a substituent,~~

~~g) a 3-membered to 14-membered non-aromatic heterocyclic group formed by R^{aN1} and R^{aN2} together in combination with the nitrogen atom to which R^{aN1} and R^{aN2} are bonded, wherein the 3-membered to 14-membered non-aromatic heterocyclic group may have a substituent,~~

~~h) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,~~

~~[[i]] a C₃ to C₁₄ cycloalkyl group which may have a substituent or~~

~~j) a 3-membered to 14-membered non-aromatic heterocyclic group which may have a substituent, or~~

~~R^{aN1}R^{aN2}N-CS-O, wherein R^{aN1} and R^{aN2} are the same as defined above,~~


~~[:,]) or a pharmacologically acceptable salt thereof, thereof.~~

~~wherein said substituents are each independently selected from the group consisting of: C₁-C₆ alkyl group, phenyl group, halogen, hydroxyl group, C₁-C₆ alkoxy group, thiol group, C₁-C₆ alkylthio group, nitro group, nitroso group, cyano group, C₁-C₆ alkoxy carbonyl group, amino group, mono (C₁-C₆ alkyl) amino group, di (C₁-C₆ alkyl) amino group, pyrrolidyl group, piperadyl group, piperidyl group and pyridyl group.~~

3. (Canceled).

4. (Currently Amended) The compound according to claim 1, wherein R⁷ and R²¹ R^{N1} and R^{N2} are the same or are different and represent a C₁ to C₆ alkyl group or C₆ to C₁₄ aryl group,

or form, together in combination with the nitrogen atom to which R^{N1} and R^{N2} are bonded, a non-aromatic heterocyclic group selected from the group consisting of:



or a pharmacologically acceptable salt thereof.

5-18. (Canceled).

19. (Currently Amended) The compound according to claim 1, which is (8E,12E,14E)-21-benzoyloxy-3,6-dihydroxy-6,10,12,16,20-pentamethyl-7-((4-methylpiperazin-1-yl)carbonyl)oxy-18,19-epoxytricoso-8,12,14-trien-11-olide, (8E,12E,14E)-21-(N,N-dimethylcarbamoyloxy)-3,6-dihydroxy-6,10,12,16,20-pentamethyl-7-((4-methylpiperazin-1-yl)carbonyl)oxy-18,19-epoxytricoso-8,12,14-trien-11-olide, (8E,12E,14E)-3,6-dihydroxy-6,10,12,16,20-pentamethyl-21-N,N-dimethylcarbamoyloxy-7-((4-methylpiperazin-1-yl)carbonyl)oxy-18,19-epoxytricoso-8,12,14-trien-11-olide and (8E,12E,14E)-3,6-dihydroxy-6,10,12,16,20-pentamethyl-7-((4-methylpiperazin-1-yl)carbonyl)oxy-21-phenylcarbamoyloxy-18,19-epoxytricoso-8,12,14-trien-11-olide; or a

pharmacologically acceptable salt thereof.

20. (Canceled).

21. (Previously Presented) A pharmaceutical composition comprising the compound according to claim 1, or a pharmacologically acceptable salt thereof as an active ingredient and a pharmaceutically acceptable carrier.

22-45. (Canceled).